Case of Guillain-Barré syndrome following COVID-19 vaccine

BMJ Case Rep. 2021 Jun 29;14(6):e243629. doi: 10.1136/bcr-2021-243629.


Guillain-Barré syndrome (GBS) is a rare immune-mediated disorder of the peripheral nerves. Although its cause is not fully understood, the syndrome often follows infection with a virus or bacteria, although in rare occasions, vaccination may precede GBS. We describe a case of a 62-year-old woman who presented with paraesthesia and progressive weakness of both lower limbs over 3 days. Clinical examination and investigation findings including lumbar puncture and nerve conduction studies were consistent with the diagnosis of GBS. She had no history of either diarrhoea or respiratory tract infections preceding her presentation. However, she had her first intramuscular dose of the Oxford/AstraZeneca COVID-19 vaccine 11 days prior to her presentation. Although no direct link could be ascertained, the purpose of this report is to highlight the incidence and consider this issue while evaluating any case of GBS in the light of the current pandemic and vaccination programme.

Keywords: COVID-19; immunological products and vaccines; peripheral nerve disease; vaccination/immunisation.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Female
  • Guillain-Barre Syndrome* / etiology
  • Humans
  • Middle Aged
  • Pandemics
  • SARS-CoV-2


  • COVID-19 Vaccines